Zachary D. Crees, MD
Assistant Professor
- Phone: 314-273-1039
- Fax: 314-454-5902
- Email: zcrees@nospam.wustl.edu
Address:
Division of Oncology
Mail Stop 8007-0029-11
Washington University
660 South Euclid Avenue
St. Louis, MO 63110 (practice location)
11th Floor Mid Campus Center (office)
Admin:
Shannon Dobbs
dobbss@wustl.edu
- Multiple Myeloma
- MDS and Leukemia
- Lymphoma
- CAR-T
- Gene and cellular immunotherapies
- Stem cell transplant
- Stem cell mobilization
I serve as the Principal Investigator or Co-Principal Investigator on seven clinical trials:
- present-2024
Phase 1 Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization (NCT06547112)
PI: Zachary Crees, Washington University School of Medicine, Division of Oncology, St. Louis, MO - present-2024
Phase 1 Multicenter, Open-Label Study of UB-VV111 in Combination with Rapamycin in Relapsed or Refractory CD19+ B-Cell Malignancies (NCT06528301)
PI: Zachary Crees, Washington University School of Medicine, Division of Oncology, St. Louis, MO - present-2023
Phase 1 Trial Evaluating Motixafortide(CXCR4 inhibitor) Alone and in Combination with Natalizumab (VLA-4 inhibitor) to Mobilize Hematopoietic Stem Cells for Gene Therapy in Sickle Cell Disease (NCT05618301)
PI: Zachary Crees, Washington University School of Medicine, Division of Oncology, St. Louis, MO - present-2020
Phase II Trial Evaluating Flotetuzumab (MGD006) for Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation (NCT04582864)
Co-PI’s: Dr. John DiPersio and Dr. Matthew Christopher, Washington University School of Medicine, Division of Oncology, St. Louis, MO - 2024-2023
Zuma-25: A Phase 2 Study of Brexucabtagene Autoleucel (KTE-X19) Chimeric Antigen Receptor T-Cell Therapy in Adult Patients with Relapsed/Refractory Rare B-Cell Malignancies (NCT05537766)
PI: Zachary Crees, Washington University School of Medicine, Division of Oncology, St. Louis, MO - 2023-2020
Phase Ib Trial Evaluating Kymriah (tisagenlecleucel) + Efineptakin Alfa (NT-I7) for Relapsed/Refractory Large B-cell Lymphoma
Co-PI’s: Dr. John DiPersio and Dr. Armin Ghobadi, Washington University School of Medicine, Division of Oncology St. Louis, MO - 2023-2020
Phase II Trial Evaluating Uproleselan (GMI-1271) as GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation for Multiple Myeloma (NCT04682405)
Co-PI’s: : Dr. Geoffrey Uy and Dr. Keith Stockerl-Goldstein, Washington University School of Medicine, Division of Oncology, St. Louis, MO
Biosketch
Education
- 2015-2011: MD (with honors), University of Illinois College of Medicine, Rockford, IL
- 2011-2008: BS in Biology (summa cum laude), University of Colorado College of Liberal Arts and Sciences, Denver, CO
Post-Graduate Training
- 2022-2020: Chief Fellow, Hematology and Oncology, Barnes-Jewish Hospital and Washington University School of Medicine, Division of Oncology, St. Louis, MO
- 2020-2019: Fellow, Hematology and Oncology, Barnes-Jewish Hospital and Washington University School of Medicine, Division of Oncology, St. Louis, MO
- 2019-2018: Chief Resident, Internal Medicine, Barnes-Jewish Hospital and Washington University School of Medicine, Department of Medicine, St. Louis, MO
- 2018-2016: Resident, Internal Medicine, Barnes-Jewish Hospital and Washington University School of Medicine, Department of Medicine, St. Louis, MO
- 2016-2015: Intern, Internal Medicine, Barnes-Jewish Hospital and Washington University School of Medicine, Department of Medicine, St. Louis, MO
Academic Positions
- present-2022: Assistant Professor, Washington University School of Medicine, Department of Medicine, Division of Oncology, Section of Bone Marrow Transplant and Leukemia, St. Louis, MO
- present-2022: Assistant Clinical Director, Center for Gene and Cellular Immunotherapy (CGCI), Washington University School of Medicine, Department of Medicine, Division of Oncology, Section of Bone Marrow Transplant and Leukemia, St. Louis, MO
University & Hospital Appointments
- 2022-2019: Program Evaluation Committee, Washington University, Heme/Onc Fellowship Program
- 2022-2019: Clinical Competency Committee, Washington University, Heme/Onc Fellowship Program
- 2019-2018: Housestaff Liaison Committee, Washington University, Medicine Residency Program
- 2019-2018: Resident Wellness Committee, Washington University, Medicine Residency Program
- 2019-2018: Clinical Competency Committee, Washington University, Medicine Residency Program
- 2019-2018: Balance in Medicine Committee, Washington University, Medicine Residency Program
Board Certification
- present-2022: ABIM Board Certified – Oncology and Hematology
- present-2018: ABIM Board Certified – Internal Medicine
Honors & Awards
- 2024: Oral Presentation, American Society of Hematology Annual Meeting
- 2022: Hanna Jean Khoury Outstanding Graduate Award, Washington University Hematology-Oncology Fellowship
- 2021: Siteman Investment Program Funding Awarded for Uproleselan Study
- 2021: Abstract Achievement Award, American Society of Hematology
- 2021: Oral Presentation, American Society of Hematology Annual Meeting
- 2021: Knowlton Incentive for Excellence Award, The Foundation for Barnes-Jewish Hospital
- 2020: Teaching Fellow of the Year, Washington University School of Medicine
- 2018: Karl-Flance Teaching Award, Washington University School of Medicine
- 2017: American College of Physicians Abstract Competition Winner 3rd place – Clinical Vignette
- 2016: Intern of the Month, Washington University, Internal Medicine Residency Program
- 2015: James Scholar Award for Outstanding Research
- 2015: American College of Physicians National Abstract Competition Winner
- 2014: Gold Humanism Honor Society
- 2014: Alpha Omega Alpha (AOA) Honor Medical Society
Professional Societies
- present-2019: American Society for Transplantation and Cellular Therapy
- present-2019: American Society of Clinical Oncology
- present-2019: American Society of Hematology